Telix Pharmaceuticals | TLX

Stock Price
13.88
Daily Change
0.28 2.06%
Monthly
-17.82%
Yearly
-23.53%
Q3 Forecast
13.73


Financials
Assets AUD 1.52B
Cash and Equivalent AUD 710.35M
Cost of Sales AUD 148.66M
Current Assets AUD 918.56M
Current Liabilities AUD 330.91M
Debt AUD 581.45M
EBIT AUD 37.44M
EBITDA AUD 33.24M
EPS Earnings Per Share AUD 0.28
Equity Capital and Reserves AUD 568.21M
Gross Profit on Sales AUD 129.12M
Interest Expense on Debt AUD 3.39M
Interest Income AUD 1.37M
Loan Capital AUD 551.82M
Market Capitalization AUD 4.41B
Net Income AUD 10.13M
Operating Expenses AUD 191.9M
Operating Profit AUD 17.72M
Ordinary Share Capital AUD 334.73M
PE Price to Earnings AUD 164.4
Pre-Tax Profit AUD 10.69M
Sales Revenues AUD 309.72M
Selling and Administration Expenses AUD 55.91M
Stock AUD 38.14M
Trade Creditors AUD 68.7M
Trade Debtors AUD 158.99M
Peers Price Chg Day Year Date
Cochlear 299.06 -0.82 -0.27% 4.42% Sep/09
CSL 208.83 -4.54 -2.13% -30.74% Sep/09
Integral Diagnostics 2.84 -0.07 -2.41% 9.23% Sep/09
Mesoblast 2.25 0.04 1.58% 145.36% Sep/09
Medical Developments International 0.58 0.01 1.75% 36.47% Sep/09
Mayne Pharma 4.58 0.08 1.78% -4.18% Sep/09
Neuren Pharmaceuticals 20.22 -0.58 -2.79% 46.42% Sep/09
Paradigm Biopharmaceuticals 0.26 -0.01 -4.73% 4.80% Sep/09
Pacific Edge 0.14 -0.001 -0.70% 34.29% Sep/09
Polynovo 1.39 -0.08 -5.44% -43.72% Sep/09
PYC Therapeutics 1.25 -0.01 -0.79% -3.85% Sep/09
Ramsay Health Care 33.63 -0.26 -0.77% -13.88% Sep/09
ResMed 42.28 0.36 0.86% 14.24% Sep/09
Sonic Healthcare 22.68 -0.29 -1.24% -15.55% Sep/09

Indexes Price Day Year Date
ASX200 8738 -111.60 -1.26% 9.06% Sep/09

Telix Pharmaceuticals Ltd traded at 13.92 this Tuesday September 9th, increasing 0.32 or 2.35 percent since the previous trading session. Looking back, over the last four weeks, Telix Pharmaceuticals gained 17.58 percent. Over the last 12 months, its price fell by 23.31 percent. Looking ahead, we forecast Telix Pharmaceuticals Ltd to be priced at 13.73 by the end of this quarter and at 13.50 in one year, according to Trading Economics global macro models projections and analysts expectations.

Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.